Clinical Trials Logo

Filter by:
NCT ID: NCT00724139 Recruiting - Knee Osteoarthritis Clinical Trials

The Effect of Training With Custom-Made Biomechanical Perturbation Platform on Kinetics, Kinematics and Electromyography in Knee Osteoarthritis Patients

Start date: January 2008
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the outcome of specific repetitive biomechanical perturbation training on motor patterns. The first hypothesis of this project is that footwear derived biomechanical challenges will convey active and passive matching biomechanical responses (i.e. kinetic, kinematic and electromyographic) trough out the musculoskeletal kinematic chain. The second hypothesis of the project is that repetitive exposure to in-situ (trough out the gait sickle) introduction to a biomechanical stimulus would generate a process of motor learning thus conveying plasticity of existing locomotor patterns and gait strategies.

NCT ID: NCT00722410 Not yet recruiting - Clinical trials for Anti-Biotic Resistance

Probiotics for Eradication of Carbapenem Resistant Klebsiella Pneumonia

Start date: September 2008
Phase: Phase 1/Phase 2
Study type: Interventional

Infection by Klebsiella pneumonia producing class A carbapenemases is a major clinical and public health problem in Israel and worldwide. The aim of this study is to determine the safety and efficacy of alteration of the gut microflora by probiotics, alone or in combination with mechanical bowel cleansing, as a strategy to eradicate colonization of the gastrointestinal tract by CRKP. We hypothesize that administration of probiotics will decrease the rate of GI colonization by CRKP.

NCT ID: NCT00722228 Recruiting - Breast Cancer Clinical Trials

Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors

Start date: July 2008
Phase: Phase 1/Phase 2
Study type: Interventional

This study is based on the finding that tumor cells that are grown in the laboratory can be modified in such a way that, when injected to the patient, they will stimulate his/her immune response. This approach will be evaluated in patients with melanoma and colorectal, gastric, ovarian, breast, lung and kidney epithelial cancer. Tumor cells grown in the laboratory will be modified to make them stimulatory to the immune system, irradiated to kill them, and injected to the patient eight times at two-week intervals. This protocol is expected to prolong survival of metastatic cancer patients.

NCT ID: NCT00722137 Completed - Clinical trials for Mantle Cell Lymphoma

Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma

Start date: May 1, 2008
Phase: Phase 3
Study type: Interventional

This is a randomized, open-label, multicenter, prospective study to compare the efficacy and safety of the combination of VcR-CAP to that of R-CHOP in participants who have newly diagnosed mantle cell lymphoma grade II, III or IV and who are ineligible to undergo bone marrow transplantation.

NCT ID: NCT00721123 Completed - Clinical trials for Rheumatoid Arthritis

A Long-term Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients With Rheumatoid Arthritis

Start date: August 2005
Phase: Phase 3
Study type: Interventional

This open-label, international multi-center extension study WA18695 was designed to assess the long term safety of tocilizumab in patients who had moderate to severe active rheumatoid arthritis (RA). Patients enrolled in the WA18695 study had previously received treatment in the 24-week, placebo-controlled, Phase III Study WA17822. Eligible patients were assigned to treatment with 8 mg/kg tocilizumab every 4 weeks for a maximum of 5 years.

NCT ID: NCT00720798 Completed - Clinical trials for Rheumatoid Arthritis

An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies

Start date: September 2005
Phase: Phase 3
Study type: Interventional

This single-arm study evaluated the long-term efficacy and safety of tocilizumab in participants who had completed treatment in the tocilizumab core studies (NCT00106522 [Roche protocol WA18062], NCT00106574 [Roche protocol WA18063], and NCT00109408 [Roche protocol WA17824]) of adults with rheumatoid arthritis. Participants received tocilizumab alone or in combination with standard anti-rheumatic treatment.

NCT ID: NCT00720252 Terminated - Fetal Lung Maturity Clinical Trials

Can Ultrasound Replace Amniocentesis for Confirming Fetal Lung Maturation Among Premature Fetuses?

Start date: July 2008
Phase: N/A
Study type: Interventional

The purpose of this study is to measure prenatally with ultrasound the intratracheal flow volume displaced during breathing cycle in premature fetuses and to check whether a relationship exists between the inspired fluid and fetal lung maturation.

NCT ID: NCT00719953 Completed - Elderly Clinical Trials

Study to Assess the Efficacy of Cognitex

Cognitex001
Start date: August 2008
Phase: Phase 4
Study type: Interventional

A Single-Center, Open Label Study to Assess the Efficacy of Cognitex in Elderly Subjects with Memory Impairment

NCT ID: NCT00719212 Completed - Ovarian Neoplasms Clinical Trials

Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer

Start date: January 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to obtain an estimate of the objective response rate (ORR) of AMG 479 in patients with recurrent platinum-sensitive ovarian epithelial (including fallopian tube and primary peritoneal) carcinoma failing frontline chemotherapy.

NCT ID: NCT00718692 Completed - Clinical trials for Immune Thrombocytopenic Purpura

Open Label Trial on the Safety and Efficacy of Sym001 in the Treatment of Immune Thrombocytopenic Purpura (ITP)

Start date: July 2008
Phase: Phase 2
Study type: Interventional

This trial is designed as a multi-centre, single-dose, exploratory dose-finding, open label trial evaluating the safety and efficacy of Sym001 in 4-9 consecutive cohorts. Subjects will receive a single IV dose of Sym001.